“Although some challenges are shared with psychotherapy and pharmacology trials more broadly, psychedelic clinical trials have to contend with several unique sources of potential bias”, write Aday et al. (2022). These methodological challenges abound: (how) can we mask participants to their treatment arm, or to the broader and intensifying hype surrounding psychedelic therapies in popular media…

Source

Previous articleHistorical Insights on the Psychedelic Renaissance
Next articleAustralia Recognises MDMA and Psilocybin as Medicines